Multiple Programs Advancing to IND and the Clinic
We are advancing several programs for the treatment of viral infectious diseases such as Herpes simplex viruses (HSV 1&2), Hepatitis B, and HIV.
View Our PipelineLeveraging Breakthroughs in CRISPR Gene Editing Technology
Excision BioTherapeutics is a CRISPR-based company developing potential cures for viral infectious diseases. The Company is pioneering a treatment modality for herpes simplex virus-1 keratitis (HSV-1 keratitis) and hepatitis B virus (HBV) that targets and inactivates the viral DNA. Leveraging the Company's multiplexed gene editing approach and virology platform, the Excision pipeline builds upon a first-generation clinical program that demonstrated positive safety and tolerability in patients with HIV. Excision’s foundational technologies were developed by Dr. Kamel Khalili at Temple University and Dr. Jennifer Doudna at UC Berkeley.
A Proprietary Dual Cut Approach that Differentiates from Other CRISPR Approaches
Targeting Viral DNA with a Novel Platform Approach
Our platform enables in silico design of probes to analyze on- and off-target effects and integrates computational methods to design the most effective guide RNAs. By optimizing on-target sequence design and minimizing off-target binding, we can maximize efficacy and minimize side effects. We are transforming drug discovery and target validation from traditional to digital.
Evolution of Excision’s CRISPR Platform for Viral Elimination
